REPLIGEN CORP
REPLIGEN CORP (RGEN): 22 pipeline candidates · ~29 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
29.3 months
D/E 0.39 · 0% dilution
N/A
22 candidates
N/A
0 buys · 1 sell (180d)
A transparent, data-derived signal for REPLIGEN CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.6B
Cash
$584.6M
Quarterly Burn
$91.0M
Runway
29.3 mo
Revenue
$194.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (22 candidates)
Showing 10 of 22 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
440
Total value held
$7.29B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 5,993,054 | $706.1M |
| vanguard capital management llc | 4,793,022 | $564.7M |
| fmr llc | 2,886,786 | $340.1M |
| united capital financial advisors, llc | 2,773,980 | $326.8M |
| vanguard portfolio management llc | 2,305,094 | $271.6M |
| state street corp | 1,777,285 | $209.4M |
| bank of new york mellon corp | 1,531,402 | $180.4M |
| maverick capital ltd | 1,518,805 | $178.9M |
| massachusetts financial services co /ma/ | 1,397,515 | $164.7M |
| invesco ltd. | 1,278,255 | $150.6M |
Showing top 10 of 440 institutional holders of REPLIGEN CORP. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in REPLIGEN CORP's pipeline?
REPLIGEN CORP (RGEN) has 22 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is REPLIGEN CORP's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, REPLIGEN CORP has approximately 29.3 months of cash runway.
What is REPLIGEN CORP's market capitalization?
REPLIGEN CORP's market capitalization is approximately $7.6B.
Who is the CEO of REPLIGEN CORP?
Mr. Olivier Loeillot is the chief executive officer of REPLIGEN CORP (RGEN).
Get the full picture on REPLIGEN CORP
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.